Results 81 to 90 of about 2,450,636 (325)
Towards Novel HIV-1 Serodiagnostic Tests without Vaccine-Induced Seroreactivity
Microbiology Spectrum, 2023 Vaccine-induced seroreactivity/positivity (VISR/P) poses a significant and common challenge to HIV vaccine implementation, as up to 95% of vaccine recipients may be misclassified as having HIV infection by current HIV screening and confirmatory ...
Ole Lagatie +12 more
doaj +1 more source
Advanced Healthcare Materials, EarlyView.Membrane vesicles derived from the probiotic Lacticaseibacillus casei BL23 demonstrate antimicrobial properties against Escherichia coli and a potential biological effect in improving the overall survival of C. elegans infected with Pseudomonas aeruginosa. These vesicles stimulated immune responses in primary cells without causing toxicity. Our results
Cecilia L. D'Antoni +11 more
wiley +1 more source
Hepatology, EarlyView., 2022 A deleterious variant of FCHSD1 results in mTOR pathway overactivation and may cause porto‐sinusoidal vascular disorder (PSVD). The pedigree of the family demonstrated an autosomal dominant disease with variable expressivity. Whole‐genome sequencing and Sanger sequencing both validated the existence of the FCHSD1 variant and the heterozygosity of c ...
Jingxuan Shan +19 more
wiley +1 more source
Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrum. [PDF]
PLoS ONE, 2012 Generation of potent anti-HIV antibody responses in mucosal compartments is a potential requirement of a transmission-blocking HIV vaccine. HIV-specific, functional antibody responses are present in breast milk, and these mucosal antibody responses may ...
James Friedman +15 more
doaj +1 more source
Multiple roles for HIV broadly neutralizing antibodies
Science Translational Medicine, 2019 Potent broadly neutralizing antibodies may be used to treat or prevent HIV and to help guide HIV vaccine design. Potent broadly neutralizing antibodies may be used to treat or prevent HIV and to help guide HIV vaccine design.
B. Haynes, D. Burton, J. Mascola
semanticscholar +1 more source
DNA Origami‐Templated Aptamer Chiral Structures Realize Cellular Enantioselectivity
Advanced Materials, EarlyView.Aptamers displayed on tubular DNA origami nanostructures in defined chiral orientations (left‐ or right‐handed) exhibit enantioselective interactions with cell surface target proteins. While the right‐handed configuration supports only transient binding, the left handedness energetically favors protein dimerization and promotes subsequent ...
Tingjie Song +9 more
wiley +1 more source
Health disparities in chronic liver disease
Hepatology, EarlyView., 2022 Abstract The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.
Ani Kardashian +3 more
wiley +1 more source
Cell Reports, 2017 Summary: Induction of broadly neutralizing antibodies (bnAbs) that target HIV-1 envelope (Env) is a goal of HIV-1 vaccine development. A bnAb target is the Env third variable loop (V3)-glycan site.
Kevin O. Saunders +34 more
doaj +1 more source
Advanced Sensor Research, EarlyView.This Review focuses on assessing and providing perspective on the field of rationally‐designed optical sensors constructed with single‐walled carbon nanotubes. The literature is reviewed and evaluated for SWCNT‐based sensors constructed with biomolecular recognition elements, including proteins, peptides, and oligonucleotides, as well as their methods ...
Amelia K. Ryan +4 more
wiley +1 more source
Identification of novel neutralizing determinants for protection against HCV
Hepatology, EarlyView., 2022 Identification of novel neutralizing determinants for protection against hepatitis C virus. Abstract Background and Aims HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
Garazi P. Alzua +12 more
wiley +1 more source